title: PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
authors.affiliation: Department of Pathology, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: D
authors.initials: D
authors.lastname: Jones
authors.affiliation: Division of Hematology, Department of Internal Medicine, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Woyach
authors.affiliation: Department of Pathology, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: W
authors.initials: W
authors.lastname: Zhao
authors.affiliation: James Polaris Molecular Laboratory, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: S
authors.initials: S
authors.lastname: Caruthers
authors.affiliation: James Polaris Molecular Laboratory, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: H
authors.initials: H
authors.lastname: Tu
authors.affiliation: Department of Pathology, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: J
authors.initials: J
authors.lastname: Coleman
authors.affiliation: Division of Hematology, Department of Internal Medicine, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Byrd
authors.affiliation: Division of Hematology, Department of Internal Medicine, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Johnson
authors.affiliation: Department of Pathology, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
authors.forename: G
authors.initials: G
authors.lastname: Lozanski
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000070538:C2 Domains / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D051966:Phospholipase C gamma / Q000235:genetics*; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; D051966:Phospholipase C gamma; D000225:Adenine